Stockscreener 앱 받기
1.07
0.00%
0.00
시간 외 거래:
1.07
전일 마감가:
$1.07
열려 있는:
$1.08
하루 거래량:
35,043
Relative Volume:
0.19
시가총액:
$35.87M
수익:
-
순이익/손실:
$-13.27M
주가수익비율:
-6.5244
EPS:
-0.164
순현금흐름:
$-7.70M
1주 성능:
+0.93%
1개월 성능:
+9.18%
6개월 성능:
-27.21%
1년 성능:
-36.31%
1일 변동 폭
$1.0301
$1.08
1주일 범위
$1.01
$1.12
52주 변동 폭
$0.8075
$2.12
Okyo Pharma Limited Stock (OKYO) Company Profile
OKYO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| OKYO | 1.07 | 35.87M | 0 | -13.27M | -7.70M | -0.164 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
OKYO Pharma (LON:OKYO) Trading Down 24.3% – Here’s What Happened - Defense World
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference - Proactive Investors USA
OKYO Pharma Advances in Ocular Treatment Trials - TipRanks
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference - The Manila Times
OKYO Pharma Limited to Present at International Tear Film & Ocular Surface Society Conference - Marketscreener.com
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trialICYMI - Proactive Investors Australia
H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares - Investing.com India
OKYO Pharma CEO Announces First Dosing in Phase 2 Trial for OK-101 to Treat Neuropathic Corneal Pain - Proactive Investors UK
OKYO Pharma doses first subject in OK-101 Phase II trial for NCP - Clinical Trials Arena
H.C. Wainwright maintains stock target, buy rating on OKYO Pharma shares By Investing.com - Investing.com South Africa
Wainwright sustains Buy rating on OKYO Pharma shares on clinical trial progress - Investing.com
OKYO Pharma launches Phase 2 trial for NCP treatment - Investing.com India
OKYO Pharma commences Phase 2 trial for ocular pain treatment By Investing.com - Investing.com Australia
OKYO Pharma launches Phase 2 trial for NCP treatment By Investing.com - Investing.com Australia
OKYO Pharma shares surge on Phase 2 neuropathic corneal pain trial update - Proactive financial news
OKYO Pharma commences Phase 2 trial for ocular pain treatment - Investing.com India
OKYO Pharma Begins Key Trial for Eye Pain Therapy - TipRanks
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - GlobeNewswire Inc.
Q2 Earnings Estimate for OKYO Pharma Issued By HC Wainwright - Defense World
H.C. Wainwright maintains Buy rating on OKYO Pharma shares By Investing.com - Investing.com UK
OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug - Yahoo Finance
OKYO Pharma begins phase 2 trial for NCP treatment - Investing.com
OKYO Pharma begins phase 2 trial for NCP treatment By Investing.com - Investing.com UK
OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment - Proactive Investors USA
OKYO begins patient enrollment for Phase 2 NCP trial By Investing.com - Investing.com Australia
OKYO begins patient enrollment for Phase 2 NCP trial - Investing.com
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma (NASDAQ:OKYO) Shares Up 3% – What’s Next? - Defense World
Neuropathic Ocular Pain Market Overview: Size, Growth - openPR
Oklo Inc. (OKLO) is looking forward to a strong quarter - SETE News
Understanding OKLO’s book value per share for better investment insights - US Post News
XTX Topco Ltd Purchases 5,759 Shares of OneMain Holdings, Inc. (NYSE:OMF) - Defense World
Multibagger Stock under Rs 20: After stock split, Ok Play allots equities upon warrants conversion - ET Now
Ok Play's board approves allotment of Equity sharesCheck details - India.com
Oklo Inc. (NYSE:OKLO) Forecasted to Post Q3 2024 Earnings of ($0.11) Per Share - MarketBeat
XTX Topco Ltd Acquires Shares of 33,954 Omega Healthcare Investors, Inc. (NYSE:OHI) - Defense World
Traders Buy High Volume of Oklo Call Options (NYSE:OKLO) - MarketBeat
Orkla India eyes public listing after completing restructuring | Company Business News - Mint
Tomohiro Okada named president, director of Universal Ent - GGRAsia
Multibagger Penny Stock Under Rs 20 Surges Over 50 Per Cent From Its 52-Week Low; Board Allots Equity Shares On Conversion Of Warrants To Promoters - Dalal Street Investment Journal
OKYO Pharma (LON:OKYO) Stock Price Down 24.3% - Defense World
Oklo Inc. (OKLO) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
OKYO Pharma executive chairman increases stake - Investing.com
OKYO Pharma executive increases stake in company By Investing.com - Investing.com Australia
OKYO Pharma executive chairman increases stake By Investing.com - Investing.com UK
OKYO Pharma executive increases stake in company - Investing.com
OKYO Pharma Chairman Boosts Stake, Advances Trials - TipRanks
Okyo Pharma announces acquisition of shares by chairman - TipRanks
OKYO Pharma Announces Chairman Acquires Shares - GlobeNewswire
Okyo Pharma Limited (OKYO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.56%
자본화:
|
볼륨(24시간):